Skip to content

Annual Review of Psychology

ISSN 0066-4308

3 papers in the library · 1,737 citations · publishing 2016-2024

Papers

Mindfulness Interventions

Annual Review of Psychology September 30, 2016 1,669 citations

A review of randomized controlled trials over the past two decades finds that mindfulness interventions—practices that train attention to present-moment experience—improve outcomes across several domains, including chronic pain, depression relapse, and addiction. The article evaluates evidence for effects on health, cognitive, affective, and interpersonal outcomes; applications in new settings such as the workplace, military, and schools; psychological and neurobiological mechanisms; dosing considerations; and potential risks. Methodologically rigorous trials demonstrate these benefits, and discussion highlights opportunities and challenges for future research and community applications.

Psychosocial and Integrative Oncology: Interventions Across the Disease Trajectory

Annual Review of Psychology September 14, 2022 Linda E. Carlson 50 citations

People diagnosed with and treated for cancer commonly experience distress, anxiety, depression, fear of recurrence, and caregiver burden, along with fatigue, pain, and sleep disturbance. This review covers psychological reactions across the disease continuum and evaluates interventions such as acceptance-based and mindfulness therapies, mind-body approaches, meaning-based therapies for advanced disease, and psychedelic therapy. It also identifies methodological shortcomings in the evidence base, offers design recommendations, and discusses future directions including pragmatic research designs, digital health interventions, and implementation science.

Therapeutic Potential of Psychedelic Drugs: Navigating High Hopes, Strong Claims, Weak Evidence, and Big Money

Annual Review of Psychology August 2, 2024 Keith Humphreys, Daniel Stjepanović, Wayne Hall et al. 18 citations

Many psychedelic drugs lack rigorous evaluation, but the science is improving. Ketamine shows promise for treatment-resistant depression despite risks like addiction and cystitis. MDMA for PTSD and psilocybin for depression, end-of-life dysphoria, and alcohol use disorder merit further replication. The mechanisms of benefit and harm remain unclear. Rigorous research is needed to assess therapeutic potential, and policies should prioritize public health over profit.